StoneX Group’s Azora Therapeutics, Inc. Common Stock AZR Stock Holding History

StoneX Group’s Portfolio AZR Stock Details AZR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-19,699	Closed	-$35.7K	–	1941
2026 Q2	$35.7K	Buy	+19,699	New	+$39K	﹤0.01%	1259
2026 Q1	–	Sell	-778	Closed	-$4.28K	–	921
2025 Q4	$4.28K	Buy	+778	New	+$6.3K	﹤0.01%	1040
2022 Q4	–	Sell	-22	Closed	-$4.83K	–	699
2022 Q3	$4.83K	Sell	22 -2	-8%	-$902	﹤0.01%	512
2022 Q2	$20.1K	Buy	+24	New	+$21.7K	﹤0.01%	641

Other funds holding AZR

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Manchester Capital Management Manchester, Vermont $736M AUM 20.83% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

Abound Wealth Management Franklin, Tennessee $537M AUM 14.21% 1-Year Est. Return

StoneX Group's AZR Position: Q3 2026 in Review

StoneX Group sold out of Azora Therapeutics, Inc. Common Stock (AZR) in Q3 2026, closing a stake of 19,699 shares — an estimated $35.7K sold.

StoneX Group first reported a position in AZR in Q2 2022 and held it in 4 quarters. The position peaked at $35.7K in Q2 2026. 7 funds tracked by Wall St. Rank hold AZR as of Q3 2026.

StoneX Group reported no remaining Azora Therapeutics, Inc. Common Stock position as of Q3 2026 after selling out during the quarter.
StoneX Group sold 19,699 Azora Therapeutics, Inc. Common Stock shares in Q3 2026, an estimated $35.7K.
StoneX Group first reported a position in Azora Therapeutics, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
StoneX Group's Azora Therapeutics, Inc. Common Stock position peaked at $35.7K in Q2 2026.
7 funds tracked by Wall St. Rank held Azora Therapeutics, Inc. Common Stock as of Q3 2026.

Based on StoneX Group's 13F filing for Q3 2026, filed 3 Nov 2026.